Long-term outcomes of cytokine therapy in pregnant women with cervical intraepithelial neoplasia
DOI: 10.32364/2618-8430-2022-5-2-106-111
Yu.E. Dobrokhotova1, E.I. Borovkova1, V.V. Romanovskaya1, I.V. Stepanyants2
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Maternity Hospital of the City Clinical Hospital No. 40, Moscow, Russian Federation
Aim: to assess long-term outcomes of exogenous cytokine therapy in pregnant women with cervical intraepithelial neoplasia (CIN).
Patients and Methods: this prospective study included 50 pregnant women with CIN. Women were randomized into two groups. Group 1 women (n=30, mean age 31.6±1.7 years) received vaginal suppositories with Superlymph 25 U. Group 2 women (n=20, mean age 29.8±1.4 years) received rectal suppositories with Superlymph 25 U. Cervical smear cytology (at baseline, 22 days after starting treatment, and 6 weeks after delivery), colposcopy, and cervical biopsy (at baseline and 6 weeks after delivery) were performed.
Results: in group 1, cytology revealed high-grade squamous intraepithelial lesion (HSIL) in 43.3%, atypical squamous cells-cannot exclude a high-grade lesion (ASC-H) in 6.7%, and atypical squamous cells of undetermined significance (ASCUS) in 10%. In group 2, cytology revealed low-grade squamous intraepithelial lesion (LSIL) in 25%, HSIL in 45%, ASC-H in 10%, and ASCUS in 20%. After the treatment course, in group 1, a regress from HSIL to LSIL was detected in 6.7%, regress from LSIL to ASCUS in 3.3%, and regress from HSIL to ASC-H in 3.3%. In group 2, NILM was detected in 5%, a regress from HSIL to LSIL in 5%, and regress from LSIL to ASCUS in 5%. Histologically, LSIL was verified in 50% of women of both groups, CIN grade 2 in 36.7% (group 1) and 40% (group 2), CIN grade 3 in 13.3% (group 1) and 10% (group 2). Six weeks after delivery, cytological abnormalities were identified in 30 women of both groups (HSIL in 56.7% and LSIL in 43.3%). Histology detected carcinoma in situ in 3.3% and CIN grade 2–3 in 53.3%. Delivery in time (on average, at 38.4±1.1 weeks of gestation) occurred in all women.
Conclusion: trend toward the improvement of cytological parameters irrespective of the mode of drug administration is reported after finishing cytokine therapy. Normalization of cytological findings was reported in 3.3% (group 1) and 5% (group 2), while improvement was reported in 6.6% (group 1) and 10% (group 2). No worsening was reported.
Keywords: cytokine therapy, pregnancy, cervical intraepithelial neoplasia, cytological study, histological study.
For citation: Dobrokhotova Yu.E., Borovkova E.I., Romanovskaya V.V., Stepanyants I.V. Long-term outcomes of cytokine therapy in pregnant women with cervical intraepithelial neoplasia. Russian Journal of Woman and Child Health. 2022;5(2):106–111 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-106-111.
About the authors:
Yuliya E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-7830-2290.
Ekaterina I. Borovkova — Dr. Sc. (Med.), Associate Professor, professor of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0001-7140-262X.
Valentiva V. Romanovskaya — C. Sc. (Med.), assistant of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-0413-5431.
Irina V. Stepanyants — obstetrician & gynecologist, Maternity Hospital of the City Clinical Hospital No. 40; 6, Taimyrskaya str., Moscow, 129336, Russian Federation.
Contact information: Irina V. Stepanyants, e-mail: apoplexia@rambler.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 10.02.2022.
Revised 10.03.2022.
Accepted 04.04.2022.
2. Clinical guidelines "Cervical intraepithelial neoplasia, erosion and ectropion of the cervix", 2020 (in Russ.).
3. Dobrokhotova Yu.E., Venediktova M.G., Grishin I.I. The effectiveness of an integrated approach to the treatment of moderate and severe cervical epithelial dysplasia against the background of human papillomavirus infection. Pharmateka. 2015;3:44–47 (in Russ.).
4. Dobrokhotova Yu.E., Gankovskaya L.V., Borovkova E.I. et al. Improving the tactics of managing pregnant women with cervical dysplasia by correcting indicators of innate immunity. Obstetrics and gynecology. 2018;12:42–49 (in Russ.).
5. Instructions for the medical use of the drug Superlymph (Electronic resource.) URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9138d8d4-ee69–4ef2–936c-2b757dc19c1b&t= (access date: 10.01.2022) (in Russ.).
6. International classification of colposcopic terms, approved in Rio de Janeiro in 2011 (Electronic resource.) URL: http://ragin-std.ru/assets/files/int-classification.pdf (access date: 10.01.2022) (in Russ.).
7. Order of the Ministry of Health of Russia dated October 20, 2020 N 1130n "On approval of the Procedure for the provision of medical care in the field of obstetrics and gynecology" (Electronic resource.) URL: http://perinatcentr.ru/files/N_1130.pdf (access date: 10.01.2022) (in Russ).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать